SCHEMBL9965914

SCHEMBL9965914

CCC(C)N1CCCC1c1ccccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
SCN3A Q9NY46 1/20 0.39
MAOB P27338 2/20 0.39
MAOA P21397 1/20 0.39
TSHR P16473 1/20 0.39
RIPK1 Q13546 2/20 0.38
MEN1 O00255 2/20 0.38
CYP3A4 P08684 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.37
ROCK2 O75116 1/20 0.36
KDM1A O60341 1/20 0.35
RCOR1 Q9UKL0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963125 0.85 ALDH1A1 (0.43) ALDH1A1GAASMN1; SMN2SCN3AMAOB
SCHEMBL24775484 0.85 ALDH1A1 (0.43) ALDH1A1GAASMN1; SMN2SCN3AMAOB
SCHEMBL22871227 0.79 CHRNB2 (0.53) SCN3ARIPK1
SCHEMBL27962869 0.79 SCN3A (0.48) ALDH1A1GAASMN1; SMN2SCN3AMAOB
SCHEMBL28317516 0.77 GAA (0.44) ALDH1A1GAASMN1; SMN2MAOBMAOA
SCHEMBL636743 0.76 MAOB (0.41) ALDH1A1GAASMN1; SMN2MAOBMAOA
SCHEMBL22005069 0.75 MAOB (0.41) ALDH1A1GAASMN1; SMN2MAOBMAOA
SCHEMBL21725646 0.75 RIPK1 (0.50) MAOBMAOATSHRRIPK1LMNA
SCHEMBL9286633 0.75 MAOA (0.44) ALDH1A1GAASMN1; SMN2MAOBMAOA
SCHEMBL24757139 0.75 CHRNB2 (0.47) ALDH1A1RIPK1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 ALDH1A1 534/4885GAA 2706/4885SMN1; SMN2 3655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.